NASDAQ:OKYO OKYO Pharma (OKYO) Stock Price, News & Analysis $3.10 +0.40 (+14.81%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.19 +0.09 (+2.90%) As of 08/1/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About OKYO Pharma Stock (NASDAQ:OKYO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OKYO Pharma alerts:Sign Up Key Stats Today's Range$2.75▼$3.1550-Day Range$1.75▼$3.1052-Week Range$0.81▼$3.15Volume799,881 shsAverage Volume145,910 shsMarket Capitalization$116.59 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company Overview OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom. Read More OKYO Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreOKYO MarketRank™: OKYO Pharma scored higher than 64% of companies evaluated by MarketBeat, and ranked 340th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOKYO Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageOKYO Pharma has only been the subject of 1 research reports in the past 90 days.Read more about OKYO Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for OKYO Pharma are expected to remain at ($0.17) per share in the coming year.Read more about OKYO Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.37% of the float of OKYO Pharma has been sold short.Short Interest Ratio / Days to CoverOKYO Pharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in OKYO Pharma has recently decreased by 26.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOKYO Pharma does not currently pay a dividend.Dividend GrowthOKYO Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.37% of the float of OKYO Pharma has been sold short.Short Interest Ratio / Days to CoverOKYO Pharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in OKYO Pharma has recently decreased by 26.50%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News SentimentN/A News SentimentOKYO Pharma has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for OKYO Pharma this week, compared to 1 article on an average week.Search Interest3 people have searched for OKYO on MarketBeat in the last 30 days. MarketBeat Follows4 people have added OKYO Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OKYO Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders40.46% of the stock of OKYO Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.97% of the stock of OKYO Pharma is held by institutions.Read more about OKYO Pharma's insider trading history. Receive OKYO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address OKYO Stock News HeadlinesOKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMIJuly 19, 2025 | proactiveinvestors.comOKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMIJuly 19, 2025 | proactiveinvestors.com379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsAugust 2 at 2:00 AM | True Market Insiders (Ad)OKYO Slides Despite Fresh R&D FundingJuly 17, 2025 | baystreet.caOKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal PainJuly 17, 2025 | finance.yahoo.comOKYO Pharma Secures $1.9 Million to Boost Urcosimod DevelopmentJuly 17, 2025 | tipranks.comOKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapyJuly 17, 2025 | proactiveinvestors.comOKYO reports top-line data from neuropathic corneal pain therapy trialJuly 17, 2025 | finance.yahoo.comSee More Headlines OKYO Stock Analysis - Frequently Asked Questions How have OKYO shares performed this year? OKYO Pharma's stock was trading at $1.1499 on January 1st, 2025. Since then, OKYO stock has increased by 169.6% and is now trading at $3.10. When did OKYO Pharma IPO? OKYO Pharma (OKYO) raised $2 million in an initial public offering on Tuesday, May 17th 2022. The company issued 625,000 shares at a price of $4.00 per share. Who are OKYO Pharma's major shareholders? OKYO Pharma's top institutional investors include Wealth Enhancement Advisory Services LLC (0.03%). View institutional ownership trends. How do I buy shares of OKYO Pharma? Shares of OKYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OKYO Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that OKYO Pharma investors own include Meta Platforms (META), Intel (INTC), NVIDIA (NVDA), C3.ai (AI), Bristol Myers Squibb (BMY), Energy Transfer (ET) and Ford Motor (F). Company Calendar Today8/02/2025Next Earnings (Estimated)8/12/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OKYO CIK1849296 Webwww.okyopharma.com Phone44-20-7495-2379FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Price Target for OKYO Pharma$7.00 High Price Target$7.00 Low Price Target$7.00 Potential Upside/Downside+125.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.40 Quick Ratio0.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-19.38Miscellaneous Outstanding Shares37,610,000Free Float22,394,000Market Cap$116.59 million OptionableNot Optionable Beta-0.09 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:OKYO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.